Drug intelligence / Profile preview

APG-2575 + daratumumab + lenalidomide + dexamethasone

Development stage: Unknown
Lead developer: Ascentage Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

This is a four-drug combination therapy investigated for the treatment of relapsed or refractory multiple myeloma. **APG-2575** is a small molecule Bcl-2 inhibitor that induces apoptosis in cancer cells overexpressing Bcl-2. **Daratumumab** is a monoclonal antibody targeting CD38 on myeloma cells, mediating immune cytotoxicity. **Lenalidomide** is an immunomodulatory agent with anti-angiogenic and direct tumoricidal effects and promotes immune response. **Dexamethasone** is a synthetic corticosteroid providing anti-inflammatory and immunosuppressive effects, commonly used as part of chemotherapy regimens[1][3][5].

Brand names: APG-2575APG2575APG 2575
Other names: daratumumab + lenalidomide + dexamethasoneDRd

Targets

CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)BCL-2 (BCL-2 family)CRBN (Cereblon)

Beyond the preview

Go deeper on APG-2575 + daratumumab + lenalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG-2575 + daratumumab + lenalidomide + dexamethasone.

Explore the full profile